TERMINET is a multicentric project funded by the European Union Horizon 2020 research and innovation program (Grant Agreement N.957406), in which Fondazione Policlinico Universitario Agostino Gemelli IRCCS participates with the Use Case Pathway of Personalised Healthcare. Its purpose is to efficiently serve the ultimate user through the development of a cutting-edge architecture that leverages innovative technologies such as Software Defined Networking (SDN), multi-access edge computing, and virtualization for IoT, allowing the application of sophisticated distributed artificial intelligence systems to market-oriented use cases.
The validation of TERMINET technology in healthcare is realized through the SUPERO protocol, a clinical study carried out at Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
SUPERO study is a non-profit observational study targeting oncology patients with indications to perform interventional radiotherapy, interventional radiology, or interventional oncology procedures. In current clinical practice, the decision to refer a patient for the procedure or not is made based on information gathered from clinical examination, mostly instrumental and laboratory tests, objective examination, and anamnestic interview history.
SUPERO study aims to assess the feasibility of a novel decision-making approach based on the preliminary prediction of post-procedural toxicity or complications, and on the early identification of frail patients. This original approach consists of a systematic acquisition of behavioral data (collected through Healthentia, a mobile application for remote patient monitoring) and integrated with Real World Data collected during routine clinical practice.
The primary goal is to create new data driven tools to support clinicians to identify frail patients in relation with the procedure, thus ensuring a personalized assistance.
In this phase, patients enrolled in the SUPERO study are integrated into the TERMINET architecture and monitored from enrollment to hospital discharge, recording their course of treatment and any episodes of toxicity and other complications that may occur.
The enrollment is ongoing: over 50 patients are already part of the study, and we plan to enroll many others until the end of the project.